FDA
-
-
-
-
-
-
-
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
-
-
-
-
-
-
-
DiaMedica Therapeutics (DMAC) Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
-
-
-
-
-
-
-
DiaMedica Therapeutics Announces $11.8 Million Private Placement
-
-
-
-
-
-
-
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
DiaMedica Therapeutics Inc. (DMAC) Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
-
-
-
-
-
-
-
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

